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INTRODUCTION  
The burden of non-alcoholic fatty liver disease 
(NAFLD)  was  a signiﬁcant clinical and public 
health issue worldwide. NAFLD was characterized 
by hepatic histological changes similar to alcohol-
induced liver injury, in patients without signiﬁcant 
alcohol consumption.  A range of histological changes 
can be seen; some patients have steatosis only 
while others have hepatic steatosis with prominent 
necro-inﬂammatory changes (steatohepatitis) 
with or without associated ﬁbrosis. Non-alcoholic 
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Background: 
Despite the prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH),  there was no treatment 
has been proven to be effective in these common diseases. Although many studies have shown that lifestyle modiﬁcations such as increasing 
physical activities and exercise could be effective in the treatment of these common diseases, the optimal strategy  was still not determined. 
According to the beneﬁcial effects of antioxidant agents in the treatment of NASH, vitamin E has been used for this purpose by some 
clinicians. We designed this study for assessing beneﬁcial effects of regular physical activity on the biochemical and imaging responses in 
patients with NASH and comparing this with vitamin E as an accepted treatment for NASH. 
Materials and Methods:
This study was Randomized and single-blind clinical trials were carried out in Gonbad-e Kavus through which a total of 30 consecutive 
patients with the ultra sonographic diagnosis of non-alcoholic steatohepatitis (NASH)were enrolled and randomized to one of the 
three  groups: Vitamin E 800 mg/day, regular physical activity, or both. 
Results:
In all treatment groups improvement  in  liver transaminases level, serum lipids and ultrasonographic grading of fatty liver occurred after 
three months of treatment. When these decrement was compared between the treatment groups, there was no statistically signiﬁcant 
difference in the value of improvement between the three groups (ANOVA:  p>0.5). I.e. all three interventions improved the biochemical 
and ultrasonographic ﬁnding of  fatty liver in the same way.  Both groups with regular exercise had signiﬁcant mean weight loss in 
comparison with the vitamin E group (a mean decrease of 3.0 kg in exercise group, 5.8 kg in subjects on regular exercise plus vitamin E 
and 0.2 kg in vitamin E group, ANOVA: p=0.04).
Conclusion:
There were no signiﬁcant differences between exercise and vitamin E alone or in combination regarding the reduction in the level 
of liver enzymes and sonographic evidences of fatty liver although both resulted in signiﬁcant improvements in biochemical 
endpoints. This implies that physical activity could be considered as effective as vitamin E in the improvement of biochemical and 
ultrasonographic presentations of NASH and the addition of Vitamin E does not offer any beneﬁts. According to the ﬁndings of this 
pilot study a full-powered study with a control group should be designed.
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steatohepatitis (NASH) may lead to cirrhosis and end 
stage liver disease in a number of patients(1,2).
According to the “Practice Guideline by the 
American Gastroenterological Association” , the 
deﬁnition of  NAFLD requires that there  was 
evidence of hepatic steatosis, either by imaging or by 
histology and  there  were  no causes for secondary 
hepatic fat accumulation such as signiﬁcant alcohol 
consumption, use of steatogenic medication or 
hereditary disorders(3).
Despite its prevalence,  there was no treatment 
has been proven to be effective in NAFLD/NASH. 
A major reason was a lack of understanding of the 
pathogenetic mechanisms. General measures of risk 
reduction, such as weight loss in the obese patients, 
effective treatment of hyperlipidemia and diabetes 
mellitus (if present) are usually recommended(4-9).
Many studies have shown that lifestyle 
modiﬁcations such as weight loss and increased 
physical activity was vital component to the treatment 
of NAFLD and metabolic Syndrome(4,10-12). The 
importance of various protocols of endurance and 
resistance exercise with or without medical intervention 
has been evaluated in many studies; however, the 
optimal strategy was not yet determined(12-22).
On the other hand, most of the patients with the 
diagnosis of NAFLD have conditions related to the 
metabolic syndrome such as obesity, hypertension 
and cardiovascular disease which makes almost 
impossible for these patients to participate in most 
protocols of the exercise programs.  
The Borg Rating of Perceived Exertion (RPE) 
was a way of measuring physical activity intensity 
level(22). Perceived exertion was how hard the 
patient feels like the body is working.  It was based 
on the physical sensations a person experiences 
during physical activity, including increased heart 
rate, increased respiration or breathing rate, increased 
sweating, and muscle fatigue. Although this was a 
subjective measure, a person's exertion rating may 
provide a fairly good estimate of the actual heart rate 
during physical activity(23). This method can be used 
for the measurement of physical activity even in the 
patients with co-morbidities. This could be suitable 
for NASH patients too. 
According to the two hypothesis in the 
pathogenesis of NASH, the ﬁrst hit involves 
accumulation of excess fat in the liver cells due to 
insulin resistance and leads to hepatic steatosis. The 
second hit concerns oxidative stress that causes lipid 
peroxidation and activates inﬂammatory cytokines 
resulting in NASH(24).
Vitamin E, a fat-soluble vitamin  were believed 
to be an important antioxidant, can ameliorate the 
effects of free radicals(25-26).
There  were    several   studies   that    have 
experimented on the use of antioxidants such as Vitamin 
E for the treatment of NAFLD or steatohepatitis. 
Based on some experiences that vitamin E could 
improve the level of liver transaminases and ﬁbrosis 
score, it has been used for the treatment of NASH by 
some hepatologists(4,27-30).
In this pilot study, we compared the effect of 
regular physical activity and high dose of Vitamin 
E alone and combination in the improvement of 
biochemical and ultrasonographic of NASH.
METHODS AND MATERIALS   
The study was carried out in Gonbad-e Kavus, 
Golestan, Iran. A total of 30 consecutive patients 
with the diagnosis of non-alcoholic steatohepatitis 
(NASH) were enrolled into the study. Recruitment 
started in September 2012. Participants of any sex or 
ethnic origin diagnosed with NASH were included on 
the basis of the following criteria:
• Age between 20-55 years old
• Ultrasonographic evidence of hepatic steatosis 
together with increased in serum ALT to above 
1.5 times the upper limit of normal (ULN) i.e. 19 
U/L in women and 30 U/L in men in two separate 
measurements with at least 3 months interval. 
• Daily alcohol intake less than 10 g in women and 
20 g in men.
Patients were excluded from the study if they had one 
of the followings:
• Diagnosis of hepatitis B, hepatitis C, autoimmune 
hepatitis, and genetic liver diseases such as 
Wilson’s disease and hemochromatosis.
• Participants presenting one or more causes that are 
commonly associated with secondary NAFLD; 
i.e., drugs, surgical procedures, environmental 
toxins, and total parenteral nutrition
• Any disease or condition which might prohibit 
physical activity
• Uncontrolled hypertension (blood pressure more 
than 140/90 mmHg)
• Presence of any diagnosed malignancy
• Presence of any co-morbid illness including 
heart failure, renal failure, respiratory failure, 
Corpulmonale, psychological disorder, or thyroid 
disorders
• Any type of Drug abuse
Eslami et.al
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• Lactation, pregnancy or planning for pregnancy 
in the next 12 months
• Use of any type of vitamin E supplementation 
• Being a professional athlete or doing regular 
exercise
The study complies with the Declaration of 
Helsinki. The Ethics Committee of the Faculty of 
Sport Sciences and Physical Education of Guilan 
University approved the protocol and the study was 
conducted in accordance with the Declaration of 
Helsinki. Written informed consent was obtained 
from each patient.
Study design: This study was a prospective 
and randomized trial with three groups. Subjects 
underwent an assessment of body weight, height, 
and blood pressure at the initial evaluation and at 
the completion of treatment 12 weeks later. Blood 
samples were obtained for assessment of complete 
blood count, fasting levels of lipids, glucose, liver 
aminotransferases and alkaline phosphatase.
Degree of fatty liver inﬁltration was assessed by 
ultrasound. The severity of steatosis is graded as mild 
(I), moderate (II), or severe (III)(31-34).
All subjects, received lifestyle advice. This 
included a verbal advice for weight loss, consumption 
of low fat diet and an increase in physical activity. 
There were no speciﬁc guidelines for how the patients 
should lose their weight. Participants were allowed to 
continue their regular drugs based on their previous 
disease but were discouraged from adding other drugs 
that are used for non-alcoholic steatohepatitis to their 
regimen. 
In    the case of newly diagnosed hyperchole-
sterolemia (LDL>130 mg/dl), treatment with 
Atorvastatin 20 mg daily and in the case of 
hypertriglyceridemia (Serum TG level>200 mg/
dl), Gemﬁbrozil 300 mg twice a day was initiated. 
In patients with elevated blood glucose level (FBS> 
126 mg/dl) treatment with metformin 500mg/day was 
started.
There was no signiﬁcant difference between 
groups in the number of patients with hyperlipidemia, 
impaired glucose tolerance test and need for receiving 
these medications (ANOVA: p>0.5), therefore 
patients which had received these medications have 
not been excluded from the study.
The planned sample size was 30 subjects, with 
equal assignments to each of the three study groups 
(10 per group). Subjects who met all eligibility 
criteria and provided written informed consent were 
randomly -using computer random number generation 
program- assigned to one of three treatment groups 
for 12 weeks: 
Group A: receiving oral vitamin E with dose of 
400 mg twice a day
Group B: receiving a regular and planned physical 
activity as the intervention group; physical activity 
was assessed objectively using a validated scale; i.e., 
the Borg’s Rating of Perceived Exertion (RPE) scale. 
Borg’s RPE scale which was provided by Borg is 
commonly used for rating of perceived effort during 
physical exercise in ergonomics and rates from 6 to 
20 (Table 1).
Patients were advised to start exercise (walking for 
at least 20 min, 3 days a week) with the Borg’s Rating 
of Perceived Exertion (RPE) scale of at least 9. They 
could raise the Borg’s RPE scale up to 14 during the 
study period and were advised to increase the duration 
of exercise from 20 minutes up to 60 minutes if they 
wished. 
Group C: Oral vitamin E with a dose of 400 mg 
twice a day plus regular physical activity as performed 
by group B.
A printed checklist was given to participants in 
group B and C and subjects were asked to record 
the duration and the intensity (based on Borg’s RPE 
scale) of their regular activity in the checklist. 
Allocation sequence was hidden in sealed 
envelopes and was controlled by another person who 
was independent to the study; so the participant’s 
allocation could not been foreseen for the investigators. 
After randomization, subjects were visited every four 
weeks for assessment of the tolerability to the study 
drugs and also for evaluation of maintaining the 
regular activity based on the previously given check 
list. Because of the type of interventions, it was not 
possible for either the participants or the investigators 
to be blinded to the treatment groups. 
Study outcomes: The primary outcome of this 
study was to assess the efﬁcacy of regular and planned 
physical activity in improving of the biochemical and/
or ultrasonographic evidence of NASH within a 12-
week period. The secondary endpoint was to assess 
the safety of such intervention.
Statistical analysis: The primary analysis was an 
intention-to-treat analysis, SPSS was used to analyze 
the data. A 2-factor analysis of variance (ANOVA) 
one-way analysis of variance test was performed for 
the analysis of qualitative variables; Chi-square test 
was used for analysis of quantitative variables. P 
values of less than 0.05 were considered to indicate 
statistical signiﬁcance. This study was a pilot study so 
Regular Physical Activity Versus Vitamin E in NASH
59
Govaresh/ Vol.20/ No.1/ Spring 2015
sample size was not calculated. Extraction of data from 
the questionnaires and analyzed them was performed 
by a person who was blinded to the treatment groups. 
RESULTS  
A total of 30 patients aged 23 up to 55 years, 10 
(33.3%) men and 20 (66.7%) women, were enrolled 
between October 2012 and April 2013.
There was no signiﬁcant difference between 
the three groups with respect to demographics 
characteristics, clinical, laboratory and 
ultrasonographic data at baseline (Table 2). All 
subjects completed the study.
Serum biochemical levels:
Decrease in mean aspartate aminotransferase, 
alaninetransferase and alkaline phosphatase levels 
among subjects in all intervention groups were 
seen after treatment. Improvement in the level of 
aspartate aminotransferase and alaninetransferase 
was statistically signiﬁcant in the subjects receiving 
vitamin E (Table 3). However, there was no signiﬁcant 
difference in the amount of improvement between the 
three groups. 
Serum lipids:
The serum level of the triglycerides, total 
cholesterol, and LDL-C was decreased in the subjects 
of all treatment groups. Among these, decrement in 
the triglycerides level was statistically signiﬁcant in 
all groups after the treatment; however, there was no 
signiﬁcant difference in the mean value of decrement 
between the intervention groups. It’s because almost 
the same numbers of patients in each group has 
hyperlipidemia and thus received medication for.
Metabolic factors:
A minor non-signiﬁcant change occurred in the 
fasting serum glucose after 12 weeks of treatment 
in the groups, as mentioned before patients received 
Metformin if they had hyperglycemia. Both groups 
with regular exercise had signiﬁcant mean weight 
loss in comparison with the vitamin E group (a 
mean decrease of 3.0 kg in exercise group, 5.8 kg in 
subjects on regular exercise plus vitamin E and 0.2 kg 
in vitamin E group, ANOVA: p=0.04)
Although there was signiﬁcant decrease in the mean 
BMI of all groups after treatment; this decrement was 
not signiﬁcantly different between the groups. 
Ultrasonographic grade:
Statistically non-signiﬁcant improvement in 
the ultrasonographic ﬁnding of fatty liver has 
been occurred in few patients of each group (p 
value=0.359). There is no signiﬁcant difference in the 
level of improvement between different groups. Table 
4 shows sonographic degrees of liver fat accumulation 
before and after treatment according to the treatment 
groups:
Exercise:
Table 5 shows the number and percentage of RPE 
scales which patients started to exercise with. 
A number of patients gradually increased the 
duration of their physical activity according to the 
given checklist and some of them also increased the 
degree of Borg’s scale during the treatment. 
Some other patients continued their activity with 
the same duration and intensity (p value=0.133). 
Several statistical analyses were made to assess the 
effect of exercise intensity and duration on the levels 
of liver enzymes and sonographic changes in patients 
(Table 5). 
There was a signiﬁcant statistical correlation 
between the intensity of the physical activity; i.e., 
Borg’s RPE score and the mean reduction in the levels 
of blood cholesterol, LDL, and alkaline phosphatase 
in the studied groups. Based on Post Hoc Analyses, 
with increasing the intensity of physical activity from 
score 8 to 14, a signiﬁcant further reduction occurred 
in cholesterol, LDL, and alkaline phosphatase levels, 
particularly in the treatment group B (Table 6). 
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Table 1: Instructions for Borg Rating of Perceived Exertion (RPE) 
Scale 
Scales Expressions
6 No exertion at all
7-8 Extremely light 
9-10 Very light: corresponds to "very light" exercise. For a 
healthy person, it is like walking slowly at his or her own 
pace for some minutes
11-12 Light
13-14 Somewhat hard: on the scale is "somewhat hard" exer-
cise, but it still feels OK to continue.
15-16 Hard (heavy)
17-18 Very hard: is very strenuous. A healthy person can still 
go on, but he or she really has to push him- or herself. It 
feels very heavy, and the person is very tired.
19 Extremely hard: on the scale is an extremely strenuous 
exercise level. For most people this is the most strenuous 
exercise they have ever experienced.
20 Maximal exertion
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DISCUSSION  
Despite the high and increasing prevalence of 
hepatitis induced by non-alcoholic fatty liver, no 
deﬁnitive cure has been found for this common 
disease so far. In addition to general measures such as 
weight loss and effective treatment of hyperlipidemia 
and diabetes, various pharmacologic and non-
pharmacologic treatments are also recommended.
Being overweight is considered as an important 
risk factor for the disease. In our study, only 3.3 
percent of patients have body mass index (BMI) lower 
than 25. In 83.3 percent of patients, BMI was between 
25 and 35, and in 13.3 percent of them, it was over 35.
We advised all study subjects to lose their 
weight. Although no speciﬁc diet was prescribed to 
the patients, the BMI was signiﬁcantly reduced in 
Table 2: Baseline characteristics of study subjects *
Characteristic Vitamin E (n=10) Exercise  (n=10)
Exercise plus Vitamin 
E (n=10)
Total(n=30) p value
Age (yr) 42.4±8.1 43.6±9.7 39.6±6.4 41.9±8 0.545
Female sex (%) 50 90 60 66.7 0.142
Turkmen Ethnic (%) 40 30 30 33.3 0.698
Alanin aminotransferase 
(U/liter)
60.30±36.61 58.30±27.24 56.60+15.02 58.40±26.81 0.958
Aspartate aminotransfer-
ase (U/liter)
35.50±12.96 43.20±17.92 38.90±12.96 39.20±14.63 0.515
Alkaline phosphatase 
(U/liter)
225.20±26.28 215.00±54.74 211.90±51.10 271.37±54.21 0.857
Triglycerides (mg/dl) 190.80±86.21 151.20±67.20 213.60±112.93 185.20±91.40 0.314
Total Cholesterol (mg/dl) 215.90±23.81 209.90±36.15 191.20±33.04 205.67±34.54 0.256
High-density lipoprotein 37.70±6.94 48.90±12.67 34.54±7.70 40.38±11.07 0.095
Low- density lipoprotein 135.50±27.48 130.00±33.35 119.32±29.17 128.27±29.84 0.483
Fasting serum 
glucose(mg/dl)
91.11±24.41 105.20±26.59 106.80±26.71 101.38±26.01 0.372
Weight (kg) 77.60±13.83 78.30±9.88 94.50±22.53 83.47±17.61 0.074
Body-mass index** 28.66±3.44 30.14±3.37 32.76±5.74 30.52±4.52 0.121
*Plus–minus values are Means±SD.
**The body-mass index is the weight in kilograms divided by the square of the height in meters.
Table 3: Mean decrease in the level of aspartate aminotransferase, alanintransferase and alkaline phosphatase levels
Intervention group Aspartate aminotransferase Alanine aminotransferase Alkaline phosphatase
Vitamin E
Before treatment 60.3 35.5 225.2
After trePatment 33.7 25.4 194.6
Mean decrease 26.5 10.1 30.6
p value 0.001 0.02 0.06
Regular exercise
Before treatment 58.3 43.2 215.0
After treatment 19.2 18.8 170.1
Mean decrease 39.1 24.4 44.9
p value 0.50 0.15 0.30
Vitamin E plus regular exercise
Before treatment 56.6 38.9 205.3
After treatment 34.2 30.4 161.8
Mean decrease 22.3 8.5 23.4
p value 0.80 0.94 0.80
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patients of all three groups after the study, which was 
irrelevant to the type of intervention. 
Among pharmacologic treatments of fatty liver, 
the effect of vitamin E in various studies has been 
shown. In our study, after three months of regular 
use of vitamin E in the Group A, the liver enzyme 
levels signiﬁcantly reduced. In our study, sonographic 
evidence of fatty liver also reduced after treatment with 
vitamin E. Similarly, reduction in aminotransferases 
with vitamin E was noted in a controlled trial 
which compared vitamin E alone to vitamin E with 
pioglitazone; however, histologic improvement was 
only seen with combined therapy(29).
Another prospective, double-blind, randomized, 
placebo-controlled trial with a total enrollment of 49 
patients was performed in 2003 by Harrison et al. All 
patients were randomized to receive either vitamins E 
and C (1000 IU and 1000 mg, respectively) or placebo 
daily for six months. Vitamin treatment resulted in 
a statistically signiﬁcant improvement in ﬁbrosis 
score. No changes were noted in inﬂammation with 
treatment and no improvement in necroinﬂammatory 
activity or ALT was seen with this combination drug 
therapy(28).
Histologic changes of fatty liver were not assessed 
in our study. The usefulness of using regular doses of 
vitamin E in improvement of histological evidence of 
fatty liver was found in a large study by Sanyel et al. in 
2010. In this clinical trial, non-diabetic patients with 
fatty liver disease were randomly divided into three 
groups of treatment with Pioglitazone (30 mg/day), 
treatment with Vitamin E (800 international units/
day), and placebo for 96 weeks. Overall improvement 
in liver histology was clearly higher in vitamin E 
group than the placebo group, while such a signiﬁcant 
improvement was not observed in the Pioglitazone 
group(35).
Treatment with antioxidant supplements 
showed a signiﬁcant, though not clinically relevant, 
amelioration of aspartate aminotransferase levels 
but not of alanine aminotransferase (ALT) levels, 
as compared to placebo or other interventions in a 
meta-analysis published in 2007.  Gammaglutamyl-
transpeptidase was decreased, in the treatment arm. 
Radiological and histological data were too limited 
to show any deﬁnite conclusions on the effectiveness 
of these agents. The authors noted that the results of 
this review is not sufﬁcient enough to strongly advice 
the antioxidant supplements for treating NAFLD or 
NASH due to the small number of trials, their low 
methodological quality, the variability in clinical and 
histological assessment, and the number of different 
antioxidant supplements which were tested(30).
Many clinicians are now using vitamin E in the 
treatment of non-alcoholic fatty liver hepatitis. 
However, according to the above-mentioned review 
and another meta-analysis by Miller (36)which 
showed that long-term use (over one year) of high-
doses of vitamin E can increase the overall mortality, 
focusing on other antioxidant treatments and physical 
activity could be useful. In addition to the beneﬁcial 
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Table 4: Sonographic grading of fatty liver before and after treatment 
Treatment group Normal Grade I Grade II Grade III
Vitamin E (A)
Before treatment 0 1 7 2
After treatment 1 3 6 0
Regular physical activity (B)
Before treatment 0 0 9 1
After treatment 2 4 4 0
Vitamin E and Regular physi-
cal activity (C)
Before treatment 0 0 5 5
After treatment 0 3 5 2
         
Table 5: Number and percentage of RPE scales of Borg’s in the 
patients
Borg’s RPE scale Number of patients Cumulative percentage 
8 15 71.4
10 2 81
12 2 90.5
14 1 100
Table 6:  Mean reduction in the level of biochemical markers consider-
ing the intensity of exercise
p value
 Patients who start
 and continue the
 physical activity
 with Borg’s scale
of 14
 Patients who start
 and continue the
 physical activity
 with Borg’s scale
of 8
Mean reduction
0.0137.1632.6Cholesterol
0.0336.717LDL
0.0155533AlkPhos
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effect of regular physical activity on fatty liver, it does 
not have any side effects and could have many other 
useful effects on the other systems.
Many studies have shown the effectiveness 
of the various types of exercise; i.e., endurance 
and resistance programs, on the radiologic and 
biochemical presentations of fatty liver. 
Hallsworth et al. randomized 19 healthy subjects 
with MRI diagnosed NAFLD to take part in 45–60 
minutes of resistance exercise three times a week for 
8 weeks, or to be in a control group. For minimizing 
the effect of weight loss, if the patients lost more than 
5% of their body weight, they were excluded from the 
study. Results showed that there was a 13% decrease in 
intrahepatic fat, recorded by MRI, in the intervention 
group with no change in the control group. There was 
an improvement in insulin resistance but no change in 
ALT or blood lipid levels(14).
Similarly, Sullivan et al. recruited and randomized 
18 participants with NAFLD in which the intervention 
group was required to carry out 30–60 minutes 
of exercise ﬁve times a week. MRI was used to 
determine the intrahepatic fat content, which showed 
a mild decrease in the intervention group compared 
to the control. Decrease in ALT occurred which was 
correlated with the decrease in intrahepatic fat in the 
intervention group(15).
These results are in contrast with the results of 
the study by Tarnopolsky in which healthy NAFLD 
patients have participated in a moderate intensity 
program of endurance exercise (stationary bike 
cycling). After a 3-month period of endurance 
exercise, improvements in ﬁtness (maximal oxygen 
consumption) and reduction in waist circumference 
were noted in both the lean and obese groups, 
regardless of sex. No change in BMI was seen. Hepatic 
lipid content, as measured by CT (liver attenuation), 
did not change post exercise, regardless of group or 
sex. Furthermore, no improvement in liver enzymes or 
insulin resistance was observed, and no measurement 
of lipid proﬁle was discussed in the trial(17).
Previous studies that were designed based on the 
effect of physical activity on fatty liver were carried on 
healthy population with relatively heavy endurance or 
resistance exercise. Doing such exercises would not 
be possible for most patients with fatty liver; since, 
according to risk factors for fatty liver, the possibility 
of other concurrent diseases such as osteoarthritis in 
obese people, heart disease in diabetics, etc. is high. 
Thus, this study was designed based on Borg’s scale 
and according to the patient’s ability to exercise. 
In our study, in both groups treated with regular 
physical activity, there was a signiﬁcant reduction in 
the content of liver fat based on ultrasound results 
(table 3). These results are in agreement with previous 
studies, while they are inconsistent with the results of 
Michael Doris study on 41 patients with NASH with 
evaluating the effects of endurance exercise. In this 
study, the liver fat content measured by CT scan did 
not change substantially after 3 months of exercise. 
Likewise, no signiﬁcant changes occurred in the 
levels of liver enzymes(37).
In our study the reduction in the levels of liver 
enzymes was seen in the groups after three months 
of treatment, this decrement was even higher in AST 
levels (table 2). Considering the high level of AST 
as a marker of disease progression to liver ﬁbrosis, 
perhaps its further decline in physical activity group 
is a sign of slowdown of cirrhosis(38).
As described above, more reduction in the levels 
of cholesterol, LDL, and alkaline phosphatase was 
seen parallel to the increase of the exercise intensity. 
However, the intensity of the exercise has no impact 
on levels of liver enzymes and sonographic evidence 
of fatty liver.
There was no signiﬁcant difference between 
treatment groups in the baseline demographic 
characteristics, diet type, levels of liver enzymes, 
other blood biochemical tests and the degree of fat 
accumulation on ultrasound; i.e., the role of these 
factors as confounder becomes less in this study.
In general, the following points are noteworthy from 
this study:
• Although three-month treatment with high 
dose vitamin E decreases the levels of liver 
aminotransferases and liver fat content in NASH 
patients, we could not say that this decrement 
is just because of Vitamin E; weight loss and 
treatment of other metabolic abnormalities such 
as hyperlipidemia and hyperglycemia might had 
a signiﬁcant effect on the results.
• The effect of vitamin E on liver histology was not 
evaluated here. 
• Performing heavy endurance or resistance 
exercise is not necessary for all patients; planned 
and regular physical activity in any intensity could 
improve the biochemical and ultrasonographic 
evidence of fatty liver. The beneﬁts of exercise 
on liver histology cannot be judged based on this 
study. 
• The use of vitamin E for three months is safe with 
no complications.
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Study limitations: 
• This study was designed as a pilot study to 
conduct a RCT with a larger sample size. Despite 
the high value of the study type (RCT), the small 
sample size precludes a deﬁnitive announcement 
on the results of the study.
• The short duration of the study is a limitation. 
Perhaps greater effects from all three interventions 
would be more apparent if the study period was 
extended.
• Histological assessment of liver is an important 
goal in the treatment of fatty liver. Liver Biopsy 
was not performed in this study because of short 
duration of the study; three-month period is 
shorter than being useful for evaluating the effect 
of the treatment on histology.
CONCLUSION  
 There were no signiﬁcant differences between 
treatment groups regarding the reduction in the level 
of the liver enzymes and sonographic evidence of 
fatty liver. This implies that physical activity could 
be considered as effective as vitamin E in improving 
of biochemical and ultrasonographic presentations 
of NAFLD. According to the possible side effects 
of long-term use of vitamin E and the undeniable 
beneﬁts of physical activity, we could conclude that 
regular physical activity can be recommended for 
the patients unwilling to take medications who seek 
low-risk methods in the treatment of fatty liver. On 
the other hand, the majority of the studies using just 
exercise interventions for the treatment of NAFLD/
NASH -such as our trial- has shown that exercise does 
improve liver markers of steatosis. We conclude that 
designing clinical trials with large sample sizes could 
help clinicians to plan and deﬁne a suitable exercise 
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